Gerresheimer AG, a prominent player in the health care sector, has recently come under the spotlight due to increased short-selling activity in the German market. The company, headquartered in Düsseldorf, Germany, specializes in the development and production of specialty products made from glass and plastic, primarily containers for various substances and medicines. Gerresheimer AG’s stock is publicly traded on the Xetra exchange, having gone public on June 11, 2007.
As of May 17, 2026, Gerresheimer AG’s close price stood at 25.12 EUR, with a market capitalization of 851,065,600 EUR. The company’s financial metrics reveal a price-to-earnings ratio of 36.154. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of 66.5 EUR on May 27, 2025, and a 52-week low of 14.83 EUR on February 25, 2026.
Recent reports from financial information providers have highlighted a net short position in Gerresheimer AG, placing it among other firms such as Evotec, FMC, Hypoport, Nagarro, Nordex, and Suss MicroTec under the EU short-selling transparency regime. This disclosure is part of a two-stage reporting framework designed to enhance market transparency and investor awareness. The mention of Gerresheimer AG in this context suggests that market participants are closely monitoring its share price movements and may be positioning for potential downside moves.
While the data do not provide detailed figures, the implication is clear: Gerresheimer AG is currently on the radar of short sellers, indicating heightened scrutiny of its shares. This increased attention from short sellers may reflect concerns about the company’s valuation and future performance, prompting investors to closely watch its financial developments and market activities.
For more information about Gerresheimer AG and its offerings, interested parties can visit the company’s website at www.gerresheimer.com .
